See more : NorthView Acquisition Corporation (NVACW) Income Statement Analysis – Financial Results
Complete financial analysis of Goldenwell Biotech, Inc. (GWLL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Goldenwell Biotech, Inc., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
- Chemistree Technology Inc. (CHM.CN) Income Statement Analysis – Financial Results
- Old National Bancorp (ONBPP) Income Statement Analysis – Financial Results
- Optiemus Infracom Limited (OPTIEMUS.BO) Income Statement Analysis – Financial Results
- Do Day Dream Public Company Limited (DDD.BK) Income Statement Analysis – Financial Results
- Sustainable Opportunities Acquisition Corp. (SOAC) Income Statement Analysis – Financial Results
Goldenwell Biotech, Inc. (GWLL)
About Goldenwell Biotech, Inc.
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. The company is developing five products, including JI MAI—bovine cardiac vascular active peptide; cartilage peptide, a type II collagen peptide; and Double Proline AG 3D active collagen peptide, as well as DNA repair tablets and sugar master tablets. The company was incorporated in 2019 and is based in Twinsburg, Ohio.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.34K | 47.80K | 15.97K | 0.00 | 0.00 |
| Cost of Revenue | 1.23K | 22.61K | 7.58K | 0.00 | 0.00 |
| Gross Profit | 1.11K | 25.19K | 8.39K | 0.00 | 0.00 |
| Gross Profit Ratio | 47.35% | 52.69% | 52.53% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 118.00K | 1.01M | 126.66K | 6.37K | 7.80K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 118.00K | 1.01M | 126.66K | 6.37K | 7.80K |
| Other Expenses | 0.00 | 8.00 | 1.29K | 44.00 | 0.00 |
| Operating Expenses | 118.00K | 1.01M | 126.66K | 6.37K | 6.93K |
| Cost & Expenses | 119.24K | 1.03M | 134.23K | 6.37K | 6.93K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 985.11K | 118.27K | 6.37K | 7.80K |
| EBITDA | -116.90K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | -4,995.51% | -2,060.89% | -740.70% | 0.00% | 0.00% |
| Operating Income | -116.90K | -985.11K | -118.27K | -6.37K | -7.80K |
| Operating Income Ratio | -4,995.51% | -2,060.89% | -740.70% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 8.00 | 1.29K | 44.00 | 870.00 |
| Income Before Tax | -116.90K | -985.10K | -116.98K | -6.32K | -6.93K |
| Income Before Tax Ratio | -4,995.51% | -2,060.87% | -732.64% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -985.11K | -118.27K | -6.37K | 870.00 |
| Net Income | -116.90K | -985.10K | -116.98K | -6.32K | -6.93K |
| Net Income Ratio | -4,995.51% | -2,060.87% | -732.64% | 0.00% | 0.00% |
| EPS | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 96.45M | 96.43M | 91.32M | 96.00M | 76.19M |
| Weighted Avg Shares Out (Dil) | 96.43M | 96.43M | 91.32M | 96.00M | 76.19M |
Source: https://incomestatements.info
Category: Stock Reports